Psychedelic Medicine
March 28, 2026
Levi Neal, Hannah E. Shaw, Brenda M. Gannon et al.
Background: There are currently three FDA-approved medications for opioid use disorder (OUD), but none of them are especially effective, some can precipitate withdrawal in dependent individuals, and all of them require daily administration. In the appropriate settings, single administrations of psychedelics can elicit persistent anti-addiction effects in humans and in laboratory animals, but...
Journal of Pharmacology and Experimental Therapeutics
January 25, 2024
Hannah E. Shaw, D. R. Patel, Brenda M. Gannon et al.
Abuse of novel arylcyclohexylamines (ACX) poses risks for toxicities, including adverse neurocognitive effects. In vivo effects of ring-substituted analogs of phencyclidine (PCP), eticyclidine (PCE), and ketamine are understudied. Adult male National Institutes of Health Swiss mice were used to assess locomotor effects of PCP and its 3-OH, 3-MeO, 3-Cl, and 4-MeO analogs, PCE and its 3-OH and...
Psychedelic medicine (New Rochelle, N.Y.)
September 1, 2023
Harpreet Kaur, Sedat Karabulut, James W Gauld et al.
10 citations
Autism spectrum disorder (ASD) encompasses a range of neurodevelopmental syndromes diagnostically characterized by deficits in social communication and social interaction and repetitive, inflexible patterns of behaviors, interests, and thoughts. ASD affects people worldwide, irrespective of race, ethnicity, or socio-economic status, with debilitating effects on employment and interpersonal...